Innovative Technology Daisy Genomics leverages proprietary optical sequencing technology that offers faster, more accurate genomic analysis without the need for extensive library preparation, presenting a compelling solution for labs seeking efficiency and precision in genome sequencing.

Strategic Partnerships Recent collaborations with Oak Ridge National Laboratory, University of Tennessee, and East Tennessee Health Innovation Alliance position Daisy Genomics for growth in cancer diagnostics and early disease detection markets, creating opportunities for equipment and service providers.

Growing Market Focus The company’s focus on epigenetic sequencing and liquid biopsy tools for colorectal cancer detection aligns with increasing demand for minimally invasive, early diagnostic solutions, indicating potential for expansion into oncology and personalized medicine segments.

Funding & Revenue With a funding of $2 million and revenue between $1 million and $10 million, Daisy Genomics is positioned as an early-stage innovator with growth potential, making it an attractive partner for investors and suppliers targeting biotech startups with scalable solutions.

Emerging Industry Presence Daisy Genomics’ engagement in cutting-edge research collaborations and its strategic focus on next-generation sequencing technologies create opportunities to tailor specialized instruments, reagents, and bioinformatics solutions to meet their advanced development needs.